Arcus Biosciences (RCUS) Receivables (2017 - 2025)
Arcus Biosciences (RCUS) posted quarterly Receivables of $18.0 million for Q1 2025, down 93.16% year-over-year from $263.0 million in Q1 2024, and down 92.74% quarter-over-quarter from $248.0 million in Q4 2024.
Arcus Biosciences (RCUS) Receivables (2017 - 2025) Analysis & Trends
Arcus Biosciences' Receivables history runs 9 years deep, the most recent figure standing at $18.0 million for Q1 2025.
- In Q1 2025, Receivables fell 93.16% year-over-year to $18.0 million; the TTM figure through Mar 2025 stood at $18.0 million (down 93.16% YoY), while the FY2024 annual figure was $248.0 million, up 504.88% from the prior year.
- Receivables for Q1 2025 stood at $18.0 million, down from $248.0 million in the prior quarter.
- The five-year high for Receivables was $749.9 million in Q4 2021, with the low at $4.8 million in Q3 2021.
- The 5-year median for Receivables is $40.2 million (2022), against an average of $124.4 million.
- The sharpest annual moves came in 2021 and 2022: Receivables jumped 14480.98% in 2021, then sank 94.27% in 2022.
- Arcus Biosciences' Receivables stood at $749.9 million in 2021, then tumbled by 94.27% to $43.0 million in 2022, then slipped by 4.65% to $41.0 million in 2023, then jumped by 504.88% to $248.0 million in 2024, then slumped by 92.74% to $18.0 million in 2025.
- Business Quant data shows RCUS's Receivables at $18.0 million in Q1 2025, $248.0 million in Q4 2024, and $244.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 18.00 Mn |
| Dec 31, 2024 | 248.00 Mn |
| Sep 30, 2024 | 244.00 Mn |
| Jun 30, 2024 | 256.00 Mn |
| Mar 31, 2024 | 263.00 Mn |
| Dec 31, 2023 | 41.00 Mn |
| Sep 30, 2023 | 55.00 Mn |
| Jun 30, 2023 | 36.00 Mn |
| Mar 31, 2023 | 37.00 Mn |
| Dec 31, 2022 | 43.00 Mn |
| Sep 30, 2022 | 30.82 Mn |
| Jun 30, 2022 | 40.22 Mn |
| Mar 31, 2022 | 34.22 Mn |
| Dec 31, 2021 | 749.90 Mn |
| Sep 30, 2021 | 4.77 Mn |
| Jun 30, 2021 | 5.40 Mn |
| Mar 31, 2021 | 9.02 Mn |
| Dec 31, 2020 | 5.14 Mn |
| Sep 30, 2020 | 4.67 Mn |
| Jun 30, 2019 | 62,000.00 |